Clinical Trials & Research
Search Clinical Trials
Clinical Trials
New Search
| Title | A Phase 2 Open-Label, Randomized Study of PARP Inhibition (Olaparib) Either Alone or in Combination With Anti-PD-L1 Therapy (Atezolizumab; MPDL3280A) in Homologous DNA Repair (HDR) Deficient, Locally Advanced or Metastatic Non-HER2-Positive Breast Cancer |
|---|---|
| Disease/Condition | Breast Cancer,Oncology (Medical/Hematologic),Neoplasms |
| Description | |
| Eligibility Criteria | Click here for eligibility requirements |
| Principal Investigator | Jesus Anampa Mesias, MD |
| Contact Name | Amanda Erakky |
| Contact Email | aerakky@montefiore.org |
| Protocol Number | 2017-8327 |
| Inclusion/Notes | This Information was obtained from ClinicalTrials.gov |
| Status | Active/Enrolling |
| Adult Clinical Trial | Yes |
| Pediatric Clinical Trial | No |
| Sub-Specialty | Medical and Hematologic Oncology - Breast |
| Adult, Pediatric, Both | Adult |
